Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era

by Kazuyuki Numakura, Yumin Muto, Sei Naito, Shingo Hatakeyama, Renpei Kato, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Syuya Kandori, Sadafumi Kawamura, Yoichi Arai, Akihiro Ito, Hiroyuki Nishiyama, Yoshiyuki Kojima, Wataru Obara, Chikara Ohyama, Norihiko Tsuchiya, Tomonori Habuchi
Published 2021-09-01